The FDA's Science Board has once again reviewed the idea of incorporating cannabinoids into dietary supplements.
At a Tuesday meeting with the FDA's public advisory committee, the panel focused on “challenges in evaluating the safety of dietary supplement and food ingredients with predicted pharmacological activity, utilizing cannabinoids as a case study.”
Drugmaker Johnson & Johnson JNJ was one of many businesses that urged health regulators to come up with rules on incorporating CBD in food and dietary supplements, reported Cannabis Wire.
One of the executives at the company’s pharmaceutical arm, Cynthia Afshari, said the regulatory body could “start to chip away” at the issue of CBD, which continues to remain unresolved.
“There are some really high-quality tools that the agency has at their disposal that could start to chip away at least at putting that high-quality kind of mechanistic information out there that they could be picked up by others,” said Afshari, vice president and global head of preclinical sciences and translational safety at the Janssen Pharmaceutical Cos.
FDA’s Health Concerns Over CBD
During the hearing, regulators acknowledged that both CBD and other cannabis extracts are available even though the FDA continues to issue warnings regarding their safety.
Patrick Cournoyer, a regulatory scientist with the FDA’s Center for Food Safety and Applied Nutrition, pointed out that CBD can lead to liver damage and also interact with prescribed medications.
Recently the FDA took “targeted actions” against several CBD vendors for selling unauthorized products for use in food-producing animals.
“The market is large and our resources are not unlimited, but we’ve prioritized products with the greatest public health risk and we’ve issued warning letters to select firms,” Cournoyer said.
Meanwhile, FDA Commissioner Dr. Robert M. Califf said the agency had made little progress on the regulatory framework around CBD products since Trump signed the Farm Bill in late 2018.
“We just know more because we’ve done more research,” Califf said at a congressional panel, further noting “the amazing plethora derivatives of the cannabis plant [are] surely quite profound and astounding and already in widespread use for a variety of means.”
Benzinga photo. Source: Image from Shutterstock
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.